Molecular Templates, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters
    • Articles
  • Pipeline
    • Overview
    • MT-6402
    • MT-8421
    • MT-0169
  • Clinical Trials
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Sep 28, 2023 4:11pm EDT

Molecular Templates Announces 1-for-15 Reverse Stock Split

Aug 11, 2023 11:22am EDT

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

Aug 10, 2023 8:08am EDT

Molecular Templates Announces Executive Leadership Changes

Aug 02, 2023 4:11pm EDT

Molecular Templates Announces Up to $40 Million Private Placement Offering

Jul 13, 2023 8:14am EDT

Molecular Templates Announces Debt Payoff and Restructuring

Jun 16, 2023 8:56pm EDT

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Jun 01, 2023 7:57am EDT

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2023 5:10pm EDT

Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

May 15, 2023 4:13pm EDT

Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

Apr 07, 2023 6:50pm EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...13
Next
© 2023 Molecular Templates, Inc. All Rights Reserved.
Twitter Linkedin
Privacy Policy Disclaimer Terms of Use Sitemap Expanded Access